Skip to content
Menu

Ligand Pharmaceuticals Incorporated LGNZZ

Full chart Compare
Set alert

Price alert · LGNZZ

All alert types
0.07 USD 0.00 (+0.00%)

As ofOct 19, 2026, 11:04 AM EDT

0.065 Day range 0.065
0.065 52-week range 0.17
YTD
0.00%
1 year
0.00%

Included in Essentials and up

Sign in to see Fair value

Discounted cash flow estimates against the price, and the P/E against its industry and sector.

Included in Essentials and up

Sign in to see Head count and owner earnings

Employees by annual report and the cash the business earns for its owners.

Included in Essentials and up

Sign in to see P/E against peers

The price to earnings ratio beside the closest competitors and their median.

Included in Essentials and up

Sign in to see Cash flow and returns

How profit turns into free cash flow, and the returns on equity, assets and capital.

Financial health

Altman Z-Score

0.59 Distress zone

Bankruptcy-risk model: below 1.81 distress, above 2.99 safe.

Piotroski F-Score

4 / 9 Average

Nine pass/fail tests of profitability, leverage and efficiency.

Valuation

P/E 0.0×
P/S 0.0×
P/B 0.0×
P/FCF 0.0×
EV/EBITDA -1.4×
EV/Sales -1.0×
FCF Yield 3327.7%

Profitability

Gross Margin 82.4%
Operating Margin 17.6%
Net Margin 46.4%
ROE 12.2%
ROIC 2.4%
ROA 8.0%

Growth (YoY)

Revenue 60.4%
Operating Income 105.0%
EPS (diluted) 1126.0%
Free Cash Flow -48.6%

Financial Health

Current Ratio 22.2×
Quick Ratio 22.0×
Debt / Equity 0.4×
Net Debt / EBITDA -1.4×
Interest Coverage 10.0×

Dividends

Dividend Yield 0.0%
Payout Ratio 0.0%

Annual · latest fiscal year ends 2025-12-31